Oncolytic HSV Melanoma Immunotherapy Simulator

TISSUE MICROENVIRONMENT (Click canvas or tumor center to inject calibrated HSV-1 bolus) Day 0 (0h post-dose)

Melanoma Cell

Healthy Stroma

Infected/Syncytium

HSV-1 Particle

Dendritic Cell

CD8+ Cytotoxic T-Cell

100%

Primary Melanoma Load

100%

Distant Abscopal Lesion

Replicating Virions

Activated CD8+ CTLs

Viral Engineering & Immunotherapy Toggles

ICP34.5 / ICP47 Deletions

Neurovirulence factor removed; confines replication strictly to tumor cells with defective PKR/IFN pathways; restores MHC-I antigen presentation.

GALV-GP-R- (Fusogenic Glycoprotein)

Gibbon ape leukemia virus glycoprotein promotes multinucleated syncytia formation, rapid lateral spread, and enhanced immunogenic cell death.

GM-CSF Cytokine Payload

Granulocyte-macrophage colony-stimulating factor enhances local dendritic cell maturation, cross-presentation of tumor neoantigens.

Systemic Anti-PD-1 Checkpoint

Nivolumab / pembrolizumab blockade prevents T-cell exhaustion, turning oncolytic-primed antigen release into systemic abscopal cures.

Mechanistic Telemetry & Cascade Log

[00:00]Tissue microenvironment initialized with refractory melanoma nodules. Click canvas or Inject button to deliver RP1 bolus.